Investor Presentaiton
Core pipeline: oncology & rare diseases
For personal use only
BMC/RD(4)
Brain
Kidney
Prostate
Phase II
Phase III
Commercial
Targeting
Molecule
Target
Radioactive Phase I
Isotope
Small molecule
Antibody
Antibody
PSMA(1)
68 Ga
TLX591-CDX (68Ga-PSMA-11, IlluccixⓇ)
PSMA
177 Lu
TLX591 (177Lu-rosopatamab)
225AC
TLX592 (225AC-RADmAbⓇ)
PSMA
Small molecule
PSMA
99m Tc
68 Ga
Small molecule
PSMA
Antibody
CA9(2)
89 Zr
TLX599-CDX (99mTc-iPSMA)*
TLX591-Sx (68Ga-PSMA-IRDye)
TLX250-CDX (89Zr-girentuximab)
Antibody
CA9
177 Lu
TLX250 (177Lu-girentuximab)
Small molecule
LAT-1(3)
18F
TLX101-CDx (18F-FET)
Small molecule
LAT-1
131
TLX101(1311-IPA)
Antibody
Antibody
CD66(5)
99m Tc
CD66
90Y
TLX66-CDX (99m Tc-besilesomab, ScintimunⓇ)
TLX66 (90Y-besilesomab)
*Registry Study
3. Large amino acid transporter 1.
Shaded arrows indicate completion expectations in the next 12 months.
1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
4. Bone marrow conditioning and rare disease.
5. Cluster of differentiation 66.
Telix Pharmaceuticals Limited (ASX: TLX)
Imaging
Therapy
Therapy (2nd Gen)
Imaging/Surgery
Imaging/Surgery
Imaging
Therapy
Imaging
Therapy
Imaging
Therapy
TELIX
PHARMACEUTICALS
20
20View entire presentation